News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Features Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más Shelley Wood December 30, 2016
News Daily News Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label? Yael L. Maxwell December 23, 2016
News Daily News Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos Shelley Wood September 28, 2016
News Daily News Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes Shelley Wood September 28, 2016
News Daily News Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6 Michael O'Riordan September 16, 2016
News Daily News Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry Michael O'Riordan September 13, 2016
News Daily News Increased Sedentary Time Ups Risk for CVD, Diabetes, and Death, the AHA Says Leah Lawrence August 18, 2016
News Daily News Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients L.A. McKeown August 11, 2016
News Daily News El Abciximab Intracoronario es Beneficioso en Pacientes Diabéticos Víctimas de STEMI L.A. McKeown August 11, 2016
Presentation Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients Presenter: Raffaele Piccolo August 10, 2016
News Daily News Los Niveles Altos de Lípidos Dictados Genéticamente Parecen Proteger Frente a la Diabetes Tipo 2 Todd Neale August 04, 2016
News Daily News Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes Todd Neale August 04, 2016
News Daily News The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response L.A. McKeown July 28, 2016
News Daily News AstraZeneca Strives to Block Generic Crestor as Observers Call Foul Michael O'Riordan July 13, 2016
News Daily News Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings Michael O'Riordan July 12, 2016